MedPath

NITTO DENKO CORPORATION

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:2
Phase 2:2

Drug Approvals

12

NMPA:12

Drug Approvals

Tulobuterol Patch

Product Name
阿米迪
Approval Number
国药准字HJ20110366
Approval Date
Oct 29, 2024
NMPA

Tulobuterol Patch

Product Name
阿米迪
Approval Number
国药准字HJ20110367
Approval Date
Oct 29, 2024
NMPA

Tulobuterol Patch

Product Name
阿米迪
Approval Number
国药准字HJ20110368
Approval Date
Oct 29, 2024
NMPA

Tulobuterol Patch

Product Name
阿米迪
Approval Number
国药准字HJ20140096
Approval Date
Oct 29, 2024
NMPA

Tulobuterol Patch

Product Name
阿米迪
Approval Number
国药准字HJ20140095
Approval Date
Oct 29, 2024
NMPA

Tulobuterol Patch

Product Name
阿米迪
Approval Number
国药准字HJ20140094
Approval Date
Oct 29, 2024
NMPA

Tulobuterol Patch

Product Name
阿米迪
Approval Number
H20110367
Approval Date
Dec 6, 2019
NMPA

Tulobuterol Patch

Product Name
阿米迪
Approval Number
H20140096
Approval Date
Dec 6, 2019
NMPA

Tulobuterol Patch

Product Name
阿米迪
Approval Number
H20110368
Approval Date
Dec 6, 2019
NMPA

Tulobuterol Patch

Product Name
阿米迪
Approval Number
H20110366
Approval Date
Dec 6, 2019
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (50.0%)
Phase 2
2 (50.0%)

JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

Phase 2
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: ND-L02-s0201 (Low Dose)
Drug: ND-L02-s0201 (High Dose)
First Posted Date
2018-05-29
Last Posted Date
2023-12-11
Lead Sponsor
Nitto Denko Corporation
Target Recruit Count
123
Registration Number
NCT03538301
Locations
🇺🇸

Banner-University Medical Center Tucson Campus, Tucson, Arizona, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Amicis Research Center, Northridge, California, United States

and more 30 locations

Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Influenza
First Posted Date
2016-11-04
Last Posted Date
2017-09-18
Lead Sponsor
Nitto Denko Corporation
Target Recruit Count
90
Registration Number
NCT02955030
Locations
🇯🇵

OPHAC Hospital, Osaka, Japan

News

No news found
© Copyright 2025. All Rights Reserved by MedPath